PRV

PATENT- OCH REGISTRERINGSVERKET
Patentavdelningen

Intyg
Certificate

PATENT- OCH REGISTRERINGSVERKET

Härmed intygas att bifogade kopior överensstämmer med de handlingar som ursprungligen ingivits till Patent- och registreringsverket i nedannämnda ansökan.

Ansökan ingavs ursprungligen på engelska.

This is to certify that the annexed is a true copy of the documents as originally filed with the Patent- and Registration Office in connection with the following patent application.

The application was originally filed in English.

(71) *Sökande* *AstraZeneca AB, Södertälje SE*
Applicant (s)

(21) *Patentansökningsnummer* *0203092-2*
Patent application number

(86) *Ingivningsdatum* *2002-10-18*
Date of filing

Stockholm, 2003-08-27

För Patent- och registreringsverket
For the Patent- and Registration Office

Hjördis Segerlund

Avgift
Fee *170:-*

PATENT- OCH REGISTRERINGSVERKET
SWEDEN

Postadress/Adress
Box 5055
S-102 42 STOCKHOLM

Telefon/Phone
+46 8 782 25 00
Vx 08-782 25 00

Telex
17978
PATOREG S

Telefax
+46 8 666 02 86
08-666 02 86

METHOD FOR THE SYNTHESIS OF A BENZIMIDAZOLE COMPOUND

The present invention relates to an improved process for the synthesis of 5-methoxy-2(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)thio)-1H-benzimidazole (pyrmetazole) used in the manufacturing of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulphinyl]-1H-benzimidazole and its (*S*)-enantiomer, known under the generic names omeprazole and esomeprazole, respectively.

Background of the invention and prior art

An efficient process for synthesis of omeprazole is described in WO 97/22603, which is hereby incorporated by reference. In the described process, there is no need for additional purification or isolation steps in between the different reaction steps and a more efficient process is hence offered. Further adding to the simplicity, the reaction sequence is carried out in one common solvent system throughout the whole process. However, there is still a need of a new, even more convenient and more efficient process for the manufacturing of pyrmetazole in higher yield and with higher purity, and which process provides increased yield of the final products, omeprazole or esomeprazole.

Summary of the invention

The object of the invention is to provide a process for the manufacturing of pyrmetazole in a high yield and with a high purity, which is especially important for the assymmetric synthesis of esomeprazole. The process is carried out without any isolation or purification of intermediates, and in one solvent system common for the reaction sequence, i.e. the reaction sequence from pyrmethyl alcohol (Ia) to pyrmetazole (Id), and to obtain a reproducible high yield of the final products, omeprazole or esomeprazole. Such a process eliminates time consuming steps for isolation or purification of intermediates and save time on avoiding solvent changes in the process, thus making the process more efficient and with a high production capacity.

The present invention is an improvement of the first two steps in the process described in WO 97/22603. The reaction sequence, from pyrmethyl alcohol (Ia) via pyrmethyl chloride (Ib) to pyrmetazole (Id), is carried out in one common solvent system, comprising a water immiscible organic solvent and water, which is used throughout the reaction sequence. The new improved process for the manufacture of 5-methoxy-2(((4-mehoxy-3,5-dimethyl-2-pyridinyl)-methyl)-thio)-1H-benzimidazole (pyrmetazole) can be described by Step 1 and Step 2 below, both performed in a water immiscible organic solvent and with a specified amount of water added:

Step 1: Conversion of pyrmethyl alcohol into pyrmethyl chloride, hereinafter referred to as chloro-dehydroxylation:

Reacting (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl alcohol (pyrmethyl alcohol) of the formula Ia



Ia

with a reagent, such as thionyl chloride, providing (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl chloride (pyrmethyl chloride) of the formula Ib



x HCl Ib;

Step 2: Coupling reaction:

Reacting (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl chloride of the formula Ib, prepared in Step 1 above, with 2-mercapto-5-methoxybenzimidazole (metmercazole) of the formula Ic



Ic

in the presence of a base such as, sodium hydroxide, providing 5-methoxy-2(((4-methoxy 3,5-dimethyl-2-pyridinyl)methyl)thio)-1H-benzimidazole (pyrmetazole) of the formula Id



Id.

The pyrmetazole is then further processed to the final products, omeprazole or esomeprazole.

The present invention provides an improvement associated to Step 1 in the manufacturing of pyrmetazole, by a more complete conversion and reproducible yield of pyrmethyl alcohol (Ia) and pyrmethyl chloride (Ib) respectively. The advantageous effect of water during the dehydroxychlorination reaction, Step 1, is surprisingly as this type of reagents are regarded as incompatible with water, i.e. thionyl chloride reacts violently with water and excess of thionyl chloride is usually hydrolysed after a reaction by an addition of water.

According to the process described in WO 97/22603 the crude product, pyrmetazole (Id), from Step 2 is further processed to omeprazole in a conseqtive reaction sequence. There is

no isolation or purification performed during the reaction sequence which is preferable with respect to process simplicity and economy. However, residues of pyrmethyl alcohol (Ia) from Step 1 have been found in the product mixture of pyrmetazole (Id) in Step 2.

It has been found that traces of pyrmethyl alcohol (Ia) have disadvantageous effects upon the oxidation of pyrmetazole (Id) to omeprazole and especially then in the asymmetric oxidation of pyrmetazole (Id) to esomeprazole. Such traces of pyrmethyl alcohol (Ia) results in reduced turnover and enantio-selectivity in the assymmetric oxidation and give a product with less purity and in lower yield. Thus, the obtained enantiomeric excess of esomeprazole is depending on a high purity of the intermediate compound pyrmetazole (Id). The impact of levels from about 1% or above of pyrmethyl alcohol have been investigated.

The presence of water in the chloro-dehydroxylation reaction, Step 1, is of outmost importance to obtain pyrmethyl chloride (Ib) and thereby pyrmetazole (Id) in high yield and with a high purity without any requirements of isolation or purification. The required amount of water may be charged from the beginning, or being added during or after the addition of a suitable reagent, such as thionyl chloride. Preferably a small amount of water is charged at the beginning of the reaction. The addition of water during the process may also be used as a way to re-start an incomplete reaction to improve the yield and product purity. The present invention provides a more efficient use of the reagent.

Furthermore, the presence of water in Step 1 provides a safer, and more robust process, as it also reduces the different risks connected with this type of reactions, i.e. accumulation of thionyl chloride or reactive reaction intermediates. Thus, avoiding the risk of a late rapid exothermic reaction to occur.

However, there exists other options to get complete and /or high conversion of pyrmethyl alcohol (Ia) in Step 1, and to avoid or minimise traces of pyrmethyl alcohol (Ia) in Step 2, These options can be, for instance, an extended reaction time, raised reaction temperature

or increased excess of thionyl chloride. However, these options are not favored in view of an effective production of the final products, omeprazole and esomeprazole.

Detailed description of the invention

The process comprising the following reaction steps:

Step 1: Pyrmethyl alcohol (Ia) + reagent → pyrmethyl chloride (Ib)

Step 2: Pyrmethyl chloride (Ib) + metmercazole (Ic) → pyrmetazole (Id)

is performed in a solvent system common for the reaction sequence, comprising a water immiscible organic solvent and a specified amount of water added. This process is used for the synthesis of pyrmetazole, an intermediate in the synthesis of omeprazole or esomeprazole.

In Step 1 the pyrmethyl alcohol (Ia) is reacted with an excess of thionyl chloride or another suitable reagent, such as cyanuric chloride, phosphorous trichloride and phosphorous pentachloride, giving an alkyl chloride; i.e. pyrmethyl chloride (Ib). The reaction is performed at a temperature of -5° C to +45 ° C, preferably between -5° C and +35 ° C, most preferably between +10 °C and +35 °C. In the case, no water is present from the beginning, the conversion of the reactants into the product, pyrmethyl chloride (Ib), will not go to completion. However, the reaction can be re-started by adding an amount of water and the reaction can be completed. Thus, if the reaction cease, it is possible to re-start it with addition of an amount of water.

According to Step 2 above, pyrmethyl chloride (Ib), provided from Step 1, is reacted with metmercazole (Ic) under alkaline conditions, e.g. an alkaline aqueous solution of metmercazole (Ic) is prepared and mixed with the pyrmethyl chloride (Ib). The reaction is preferably carried out at a temperatue of +30 to +60°C during a prolonged period of time. Metmercazole (Ic) is charged in approximately stoichiometric amount to the pyrmethyl chloride (Ib). The invention may also be used in combination with a phase transfer catalyst, for instance a quarternary amine, such as tetrabutyl ammonium bromide. The two phases

formed are separated and the aqueous phase may be extracted with a water immiscible organic solvent such as toluene.

As pyrmethyl alchol (Ia) has a disadvantageous effect on the following reaction steps, it is important to minimise the content of the pyrmethyl alcohol (Ia) present.

The reaction sequence according to Step 1 and Step 2 described above, is carried out in one solvent system. The solvent system used for the present process comprises a water immiscible organic solvent, such as halogenated, aliphatic and aromatic hydrocarbons or esters, for example toluene, ethyl acetate and methylene chloride, and a specified amount of water added. Preferably, toluene may be used as the water immiscible organic solvent.

More specifically, the aim with the present invention has been to improve Step 1, the dehydroxyhalogenation step, in the process for preparation of pyrmetazole (1d) used in the synthesis of omeprazole or esomeprazole, i.e. to obtain a more efficient conversion of the pyrmethyl alcohol (Ia), a reaction step that is common for both the synthesis of esomeprazole and omeprazole. It has, surprisingly, been shown that presence of a specified amount of water reduces the amount of remaining pyrmethyl alcohol (Ia) i.e. the conversion of pyrmethyl alcohol (Ia) according to Step 1 is more complete. A small amount of water present in the reaction mixture lead to a better conversion, and a more efficient use of pyrmethyl alcohol (Ia) and a product of high yield and high purity.

The water content in the solvent system shall preferably be near or above the saturation point of the organic solvent used. By this, a higher amount of pyrmethyl alcohol (Ia) is allowed to react and form the pyrmethyl chloride (Ib). The amount of water may be added before, during or after the charging of the reagent, such as thionyl chloride. An optimum range of water present during Step 1, when using toluene, is between 0.3 and 5 mg/ml, preferably between 0.4 and 2.4 mg/ml, and most preferably between 1.0 and 2.4 mg/ml. If the water content is lower than the saturation point of the organic solvent used i.e. 0.3 mg/ml of toluene the reaction is slow and it has a tendency to stop before full conversion

has been achieved (in average, a conversion of 25-50 % is obtained when dry toluene is used as the solvent system). Such a reaction leads to a high content of pyrmethyl alcohol (Ia) in the reaction mixture after Step 1. It is inconvenient to have a high content of pyrmethyl alcohol present in the crude product of pyrmetazole (Id) after Step 2. We have found that if about 1 %, or more, of pyrmethyl alcohol (Ia) is left in the reaction mixture, this component has an adverse effect on both the turnover and the enantioselectivity achieved in the assymmetric oxidation of pyrmetazole into esomeprazole.

The examples that follow will further illustrate the improved process of the invention. These examples are not intended to limit the scope of the invention as defined hereinabove or as claimed below.

EXAMPLES

Example 1

Pyrmethyl alcohol, 8.82 g (52.7 mmol), was dissolved in toluene, saturated with water, 74 ml (water content 0.4 mg/ml according to Karl Fisher). To the stirred solution, at 10°C, thionyl chloride, 8.15 g (68.5 mmol), was added slowly over 60 minutes (flow rate 0.083 ml/min). A white precipitate was formed. The conversion of pyrmethyl alcohol into pyrmethyl chloride was followed by HPLC, (column: Nova-Pak C 18, 4 µm, 3.9*150 mm; mobile phase: acetonitril: THF:50 mM MaFB, pH 3.0, 20 mM heptane sulfonic acid 16:6:78; flow: 1.0 ml/min; wave length: 264 nm). A fast reaction was recorded, reaching 99 % conversion after completed addition of thionyl chloride.

Example 2

Pyrmethyl alcohol, 8.81 g (52.6 mmol), was dissolved in a mixture of "dry" toluene, 75 ml (water content 0.04 mg/ml according to Karl Fisher) and water, 180 µl (10 mmol, equivalent to about 2.4 mg /ml of water in toluene). To the stirred solution, at 10°C, thionyl chloride, 8.15 g (68.5 mmol), was added slowly over 60 minutes (flow rate 0.083 ml/min). A white precipitate was formed. The conversion of pyrmethyl alcohol into pyrmethyl chloride was followed by HPLC as in Example 1. A fast reaction was recorded, reaching 99 % conversion after completed addition of thionyl chloride. The reaction temperature was adjusted to 20°C and methanol, 40 ml, was added to stop the reaction. A solution of the crude product, pyrmethyl chloride was obtained, with a purity of 99.6 % (HPLC), and with a pyrmethyl alcohol residue of 0.3 %.

Example 3

Pyrmethyl alcohol, 8.82 g (52.7 mmol), was dissolved in "dry" toluene, 75 ml (water content 0.04 mg/ml according to Karl Fisher). To the stirred solution, at 10°C, thionyl chloride, 8.15 g (68.5 mmol), was added slowly over 60 minutes (flow rate 0.083 ml/min). A white precipitate was formed immediately. The obtained reaction mixture was stirred and the reaction followed by HPLC as in Example 1 for an additional 3.5 hours (conversion declined and stopped at about 30%). Water, 180 µl (10 mmol), was added, to re-start the reaction, yielding a high conversion (> 90%) within 30 minutes after the addition.

CLAIMS.

1. A process for the manufacture of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]-thio]-1H-benzimidazole from (4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl alcohol comprising the following reaction steps carried out in a consecutive order in one main solvent system without isolation of the intermediates formed during the process

Step 1:

reacting (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl alcohol (pyrmethyl alcohol) of the formula Ia



Ia

with a reagent, providing (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl chloride (pyrmethyl chloride) of the formula Ib



Ib;

Step 2:

reacting (4-methoxy-3,5-dimethyl-2-pyridinyl)methyl chloride of the formula Ib, prepared in Step 1 above, with 2-mercapto-5-methoxybenzimidazole (metmercazole) of the formula Ic



Ic

in the presence of a base, providing 5-methoxy-2[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole (pyrmetazole) of the formula Id



Id

characterized in that the solvent system, common for the whole reaction sequence, comprises water immiscible organic solvent with a specified amount of water added.

2. A process according to claim 1 wherein the water immiscible organic solvent is toluene.

3. A process according to claim 1 wherein the water immiscible organic solvent is ethyl acetate.

4. A process according to claim 1, characterized in that the specified amount of water is present from the start of the reaction according to Step 1.

5. A process according to any one of claims 1 and 4, characterized in that the specified amount of water is added during the charging of the reagent in the reaction according to Step 1.

6. A process according to any one of claims 1 to 5, characterized in that the specified amount of water is added after charging of the reagent in the reaction according to Step 1.

7. A process according to any one of claims 1 to 6, characterized in that the specified amount of water is between 0.3 and 5.0 mg/ml of water immiscible organic solvent.

8. A process according to claim 7, characterized in that the specified amount of water is 0.4 – 2.4 mg/ml of water immiscible organic solvent.

9. A process according to claim 8, characterized in that the specified amount of water is 1.0 – 2.4 mg/ml of water immiscible organic solvent.

10. A process according to any one of claims 1 to 9, characterized in that the reaction according to Step 1 is carried out at a temperature between -5°C and +45°C.

11. A process according to claim 10, characterized in that the temperature is between -5°C and +35°C.

12. A process according to claim 11, characterized in that the temperature is between +10°C and +35°C.

13. A process according to any one of claims 1 to 12, characterized in that the reagent is thionyl chloride.

14. 5-methoxy-2[[(4-methoxy-3,5-di,ethyl-2-pyridinyl)methyl]thio]-1H-benzimidazole (pyrmetazole) prepared according to any of the claims 1 to 13.

ABSTRACT

A process for the manufacture of omeprazole or esomeprazole from pyrmethyl alcohol via pyrmethyl chloride and pyrmetazole characterized in that the whole reaction sequence is carried out without any isolation or purification of intermediates. Further, the reaction is carried out in a solvent system common for the whole reaction sequence and inert to the reactants formed during the process and used in the process and comprises a water immiscible organic solvent and a specified amount of water.